Savara Inc. (SVRA) |
| 5.66 -0.21 (-3.58%) 04-10 16:00 |
| Open: | 5.87 |
| High: | 5.905 |
| Low: | 5.48 |
| Volume: | 1,801,748 |
| Market Cap: | 1,158(M) |
| PE Ratio: | -10.68 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.10 |
| Resistance 1: | 6.08 |
| Pivot price: | 5.42 |
| Support 1: | 5.30 |
| Support 2: | 4.81 |
| 52w High: | 7.005 |
| 52w Low: | 1.89 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Financials
| EPS | -0.530 |
| Book Value | 0.800 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.398 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -32.9 |
| Return on Equity (ttm) | -63.5 |
Company news
Fri, 10 Apr 2026
Savara Inc. (NASDAQ: SVRA) proxy: MOLBREEVI FDA date, equity and vote items - Stock Titan
Thu, 09 Apr 2026
Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy - simplywall.st
Tue, 07 Apr 2026
SVRA: MOLBREEVI shows strong efficacy and safety for autoimmune PAP, targeting a $2B+ U.S. market - TradingView — Track All Markets
Tue, 07 Apr 2026
Savara (SVRA) Advances with Regulatory Reviews for Molbreevi - GuruFocus
Tue, 07 Apr 2026
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Wed, 01 Apr 2026
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
